Orocobre (ORL) PT Lowered to C$8.70

Orocobre (TSE:ORL) had its target price dropped by research analysts at Eight Capital from C$9.10 to C$8.70 in a note issued to investors on Friday. Eight Capital’s price objective would suggest a potential upside of 76.83% from the stock’s current price.

Shares of TSE ORL opened at C$4.92 on Friday. Orocobre has a 52-week low of C$2.73 and a 52-week high of C$7.36.

TRADEMARK VIOLATION NOTICE: “Orocobre (ORL) PT Lowered to C$8.70” was originally reported by Ticker Report and is owned by of Ticker Report. If you are accessing this story on another site, it was illegally stolen and reposted in violation of international copyright legislation. The legal version of this story can be viewed at https://www.tickerreport.com/banking-finance/3339588/orocobre-orl-pt-lowered-to-c8-70.html.

Orocobre Company Profile

Orocobre Limited operates primarily in Argentina in the mining industry. The Company engages in the production ramp up of its Olaroz Lithium Facility and the operation of Borax Argentina SA (Borax Argentina). Its segments include Corporate, the Olaroz project, South American Salars and Borax Argentina.

Receive News & Ratings for Orocobre Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orocobre and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

New Age Beverages  Stock Price Down 9.4% on Analyst Downgrade
New Age Beverages Stock Price Down 9.4% on Analyst Downgrade
Scotiabank Reiterates C$4.75 Price Target for Premier Gold Mines
Scotiabank Reiterates C$4.75 Price Target for Premier Gold Mines
BMO Capital Markets Increases Roots  Price Target to C$16.00
BMO Capital Markets Increases Roots Price Target to C$16.00
Syntel  Trading -0.6% Higher  After Strong Earnings
Syntel Trading -0.6% Higher After Strong Earnings
BNP Paribas Reiterates CHF 74 Price Target for Nestle
BNP Paribas Reiterates CHF 74 Price Target for Nestle
Roche  Given a CHF 230 Price Target at Morgan Stanley
Roche Given a CHF 230 Price Target at Morgan Stanley


Leave a Reply

© 2006-2018 Ticker Report. Google+.